December 8, 2025BloodOpen Access

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

View Full Paper

Ask AI

Bookmark

Authors

CWChad WrightUniversity of Cincinnati KDKelly DavisonRoyal Victoria Regional Health Centre APAngela PunnettUniversity of Toronto

Discussion

Member takes

Implication

Observational analysis indicates FDG-PET predicts lower progression-free survival in Hodgkin lymphoma with nivolumab-AVD, suggesting recapitalization may be necessary.

Key Points

Progression-free survival was lower in patients with positive FDG-PET after treatment, emphasizing its limited predictive value.
Ninety-four percent 3-year progression-free survival was seen in patients with negative iPET and EoT PET results.
Analysis of 994 patients treated with either nivolumab-AVD or brentuximab vedotin-ABVD revealed significant outcomes based on PET readings.
This study highlights the need for ongoing evaluation of alternative response assessment modalities in Hodgkin lymphoma.

Cite This Study

Wright et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d901 https://doi.org/10.1182/blood-2025-1851

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis indicates FDG-PET predicts lower progression-free survival in Hodgkin lymphoma with nivolumab-AVD, suggesting recapitalization may be necessary.

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider